Zevra Therapeutics (ZVRA) Times Interest Earned (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Times Interest Earned of $30.48 for Q1 2026, up 1058.31% on a QoQ basis from -$3.18 in Q4 2025, and up 3413.7% year-over-year from $0.87 in Q1 2025.
Zevra Therapeutics (ZVRA) Times Interest Earned (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Times Interest Earned history runs 13 years deep, the most recent figure standing at $30.48 for Q1 2026.
- Quarterly Times Interest Earned rose 3413.7% year-over-year to $30.48 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.91 (up 84.49% YoY) and the FY2025 annual result came in at -$0.69, down 15.72% from the prior year.
- Times Interest Earned was $30.48 for Q1 2026 at Zevra Therapeutics, up from -$3.18 in the prior quarter.
- Across five years, Times Interest Earned topped out at $78.53 in Q4 2023 and bottomed at -$146.82 in Q4 2024.
- A 5-year average of -$13.86 and a median of -$6.94 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned plunged 914.93% — and 2026, when it soared 3413.7%.
- Zevra Therapeutics' Times Interest Earned stood at -$26.09 in 2022, then surged by 401.05% to $78.53 in 2023, then sank by 286.95% to -$146.82 in 2024, then jumped by 97.83% to -$3.18 in 2025, then jumped by 1058.31% to $30.48 in 2026.
- Business Quant data shows ZVRA's Times Interest Earned at $30.48 in Q1 2026, -$3.18 in Q4 2025, and $2.02 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 30.48 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.48 |
| Dec 31, 2025 | -3.18 |
| Sep 30, 2025 | 2.02 |
| Jun 30, 2025 | -35.36 |
| Mar 31, 2025 | -0.92 |
| Dec 31, 2024 | -146.82 |
| Sep 30, 2024 | -4.20 |
| Jun 30, 2024 | -11.28 |
| Mar 31, 2024 | -3.30 |
| Dec 31, 2023 | 78.53 |
| Sep 30, 2023 | -41.98 |
| Jun 30, 2023 | -31.74 |
| Mar 31, 2023 | -9.67 |
| Dec 31, 2022 | -26.09 |
| Sep 30, 2022 | -4.14 |
| Jun 30, 2022 | -14.15 |
| Dec 31, 2021 | -218.62 |
| Sep 30, 2021 | -52.90 |
| Jun 30, 2021 | 2.82 |
| Mar 31, 2021 | 34.97 |